186 related articles for article (PubMed ID: 24944371)
1. Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-week, open-label, dose-increasing study.
Homma Y; Homma K; Iizuka S; Iigaya K
Curr Ther Res Clin Exp; 2003 Apr; 64(4):236-47. PubMed ID: 24944371
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of low-dose rosuvastatin on plasma levels of cholesterol and oxidized low-density lipoprotein in 3 ultracentrifugally separated low-density lipoprotein subfractions.
Homma K; Homma Y; Ozawa H; Shiina Y; Shibata T; Yoshida T; Hasegawa K; Kanda T; Tokuyama H; Wakino S; Hayashi K; Itoh H; Hori S
J Clin Lipidol; 2015; 9(6):751-757. PubMed ID: 26687695
[TBL] [Abstract][Full Text] [Related]
3. Decrease in plasma low-density lipoprotein cholesterol, apolipoprotein B, cholesteryl ester transfer protein, and oxidized low-density lipoprotein by plant stanol ester-containing spread: a randomized, placebo-controlled trial.
Homma Y; Ikeda I; Ishikawa T; Tateno M; Sugano M; Nakamura H
Nutrition; 2003 Apr; 19(4):369-74. PubMed ID: 12679174
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.
Bevilacqua M; Guazzini B; Righini V; Barrella M; Toscano R; Chebat E
Curr Ther Res Clin Exp; 2004 Jul; 65(4):330-44. PubMed ID: 24672088
[TBL] [Abstract][Full Text] [Related]
5. Effects of low-dose simvastatin on the distribution of plasma cholesterol and oxidized low-density lipoprotein in three ultra-centrifugally separated low-density lipoprotein subfractions: 12- month, open-label trial.
Homma Y; Michishita I; Hayashi H; Shigematsu H;
J Atheroscler Thromb; 2010 Oct; 17(10):1049-53. PubMed ID: 20644333
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
7. Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia.
Inami S; Okamatsu K; Takano M; Takagi G; Sakai S; Sano J; Mizuno K
Jpn Heart J; 2004 Nov; 45(6):969-75. PubMed ID: 15655272
[TBL] [Abstract][Full Text] [Related]
8. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
9. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin.
Lagrost L; Athias A; Lemort N; Richard JL; Desrumaux C; Châtenet-Duchêne L; Courtois M; Farnier M; Jacotot B; Braschi S; Gambert P
Atherosclerosis; 1999 Apr; 143(2):415-25. PubMed ID: 10217372
[TBL] [Abstract][Full Text] [Related]
10. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action.
Winkler K; Abletshauser C; Hoffmann MM; Friedrich I; Baumstark MW; Wieland H; März W
J Clin Endocrinol Metab; 2002 Dec; 87(12):5485-90. PubMed ID: 12466341
[TBL] [Abstract][Full Text] [Related]
11. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
van Tits LJ; Smilde TJ; van Wissen S; de Graaf J; Kastelein JJ; Stalenhoef AF
J Investig Med; 2004 Apr; 52(3):177-84. PubMed ID: 15222407
[TBL] [Abstract][Full Text] [Related]
12. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
[TBL] [Abstract][Full Text] [Related]
13. Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia.
Homma Y; Kobayashi T; Yamaguchi H; Ozawa H; Sakane H; Nakamura H
Atherosclerosis; 1997 Mar; 129(2):241-8. PubMed ID: 9105567
[TBL] [Abstract][Full Text] [Related]
14. Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia.
Isaacsohn JL; LaSalle J; Chao G; Gonasun L
Clin Ther; 2003 Mar; 25(3):904-18. PubMed ID: 12852707
[TBL] [Abstract][Full Text] [Related]
15. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.
Guérin M; Dolphin PJ; Talussot C; Gardette J; Berthézène F; Chapman MJ
Arterioscler Thromb Vasc Biol; 1995 Sep; 15(9):1359-68. PubMed ID: 7670950
[TBL] [Abstract][Full Text] [Related]
16. Skew of plasma low- and high-density lipoprotein distributions to less dense subfractions in normotriglyceridemic chronic kidney disease patients on maintenance hemodialysis treatment.
Homma K; Homma Y; Shiina Y; Wakino S; Suzuki M; Fujishima S; Hayashi K; Hori S; Itoh H
Nephron Clin Pract; 2013; 123(1-2):41-5. PubMed ID: 23752220
[TBL] [Abstract][Full Text] [Related]
17. Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women.
Maki KC; Dicklin MR; Davidson MH; Mize PD; Kulkarni KR
Vasc Health Risk Manag; 2012; 8():31-8. PubMed ID: 22272073
[TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy.
O'Byrne D; Devaraj S; Islam KN; Collazo R; McDonald L; Grundy S; Jialal I
Metabolism; 2001 Feb; 50(2):207-15. PubMed ID: 11229431
[TBL] [Abstract][Full Text] [Related]
19. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia.
Homma Y; Ozawa H; Kobayashi T; Yamaguchi H; Sakane H; Mikami Y; Mikami Y; Nakamura H
Atherosclerosis; 1994 Apr; 106(2):191-201. PubMed ID: 8060379
[TBL] [Abstract][Full Text] [Related]
20. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
